Top Healthcare Stocks to Buy and Hold as Long-Term Investments

While healthcare equities underperformed the broader market last year, savvy investors shouldn’t overlook the compelling opportunities that still exist within the sector. We’ve identified three exceptional healthcare companies that deserve a permanent place in any long-term portfolio: Eli Lilly (NYSE: LLY), AbbVie (NYSE: ABBV), and Intuitive Surgical (NASDAQ: ISRG). These stocks represent some of the best healthcare stocks to buy for investors with $5,000 ready to deploy today. Let’s examine what makes each of these companies worthy of your capital over the decades ahead.

Eli Lilly: Innovation Meets Market Dominance

Eli Lilly claimed a historic achievement in 2025 when it became the first pharmaceutical company to reach a trillion-dollar valuation. This milestone wasn’t accidental—it reflects the drugmaker’s commanding position in one of the fastest-growing therapeutic areas available today.

The company’s weight-loss portfolio stands as its primary growth engine. Tirzepatide, which gained approval for weight management, diabetes, and obstructive sleep apnea, captured the title of the world’s best-selling medication in 2025. This franchise should generate substantial revenue expansion for years to come. Reinforcing this momentum, Eli Lilly expects to introduce Orforglipron, an oral weight-loss and diabetes treatment, sometime in 2026. The combination of these products positions the company to command the emerging weight-loss market.

Beyond its blockbuster weight-loss drugs, Eli Lilly demonstrates genuine innovation across multiple therapeutic domains. The company is advancing treatments in immunology and oncology while simultaneously building a supercomputer designed to accelerate drug development—a competitive advantage that could yield discoveries across its entire portfolio. This multifaceted approach to innovation, combined with fortress-like financial results, makes Eli Lilly an outstanding candidate for permanent portfolio residence. At current valuations, investors can acquire approximately four shares with a $5,000 investment.

AbbVie: Resilience and Dividend Strength

AbbVie represents a different breed of healthcare investment—one built on portfolio diversification, operational excellence, and shareholder returns. The company’s core growth engines, Skyrizi and Rinvoq, are immunosuppressants that address multiple patient populations. Its Botox franchise and broader product lineup add meaningful diversification to reduce reliance on any single treatment.

What truly separates AbbVie is how successfully the company navigated one of the pharmaceutical industry’s most challenging transitions. When Humira, its former best-selling drug, lost patent protection in 2023, most observers questioned the company’s ability to sustain profitability. AbbVie’s answer was unambiguous: strong pipeline execution and new product launches. The company’s extensive development pipeline provides ample room to discover the next generation of billion-dollar products before other major patent expirations occur.

Perhaps most compelling for long-term holders is AbbVie’s dividend track record. The company belongs to the exclusive Dividend Kings club, having increased its annual payout for 50 consecutive years. This combination of pipeline depth, operational proficiency, and capital return discipline makes AbbVie a textbook example of a best healthcare stock to buy for income-focused investors. A $5,000 investment at current market levels provides access to approximately 23 shares.

Intuitive Surgical: Sustainable Competitive Advantage

Intuitive Surgical occupies a unique position in medical device markets through its leadership in robotic-assisted surgery systems. The da Vinci platform dominates its category and benefits from a durable competitive moat that traditional financial analysis often underestimates.

The switching costs embedded in this business are formidable. Once hospital systems purchase a da Vinci system, they invest heavily in surgeon training and institutional knowledge. This integration into surgical education, residency programs, and continuing medical education creates sticky relationships that make competitors’ products unattractive despite any technological parity. This explains why Intuitive Surgical should maintain leadership in robotic surgery even as larger rivals intensify competitive efforts.

The company’s revenue engine depends fundamentally on procedure volume expansion—a metric that trends favorably. As Intuitive Surgical earns additional clinical indications for da Vinci, surgeons adopt the platform for new procedures, driving demand for the instruments and disposable accessories that generate high-margin revenue. The global aging demographic also works in Intuitive Surgical’s favor, as older populations require more surgical interventions. Combined with strong financial performance and expanding installed base, these factors suggest the company will deliver competitive returns for decades. A $5,000 stake purchases roughly nine shares at current levels.

Building Your Healthcare Portfolio Today

The intersection of demographic trends, innovative pipelines, and market leadership across these three companies creates a compelling case for long-term investors. Whether you prioritize growth innovation like Eli Lilly, dividend sustainability like AbbVie, or competitive moat strength like Intuitive Surgical, all three represent among the best healthcare stocks to buy for buy-and-hold portfolios constructed today. Consider your risk tolerance and investment timeline, but each deserves serious consideration for permanent holdings within a diversified portfolio.